These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31986451)

  • 21. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
    Spetsieris N; Boukovala M; Weldon JA; Tsikkinis A; Hoang A; Aparicio A; Tu SM; Araujo JC; Zurita AJ; Corn PG; Pagliaro L; Kim J; Wang J; Subudhi SK; Tannir NM; Logothetis CJ; Troncoso P; Wang X; Wen S; Efstathiou E
    Clin Genitourin Cancer; 2021 Feb; 19(1):22-31.e5. PubMed ID: 32675015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
    Carles J; Alonso-Gordoa T; Mellado B; Méndez-Vidal MJ; Vázquez S; González-Del-Alba A; Piulats JM; Borrega P; Gallardo E; Morales-Barrera R; Paredes P; Reig O; Garcías de España C; Collado R; Bonfill T; Suárez C; Sampayo-Cordero M; Malfettone A; Garde J
    Eur J Cancer; 2022 Sep; 173():317-326. PubMed ID: 35981452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.
    Yang YJ; Lin GW; Li GX; Dai B; Ye DW; Wu JL; Xie HY; Zhu Y
    Asian J Androl; 2018; 20(2):184-188. PubMed ID: 29111539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
    Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
    [No Abstract]   [Full Text] [Related]  

  • 28. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
    Attard G; de Bono JS; Logothetis CJ; Fizazi K; Mukherjee SD; Joshua AM; Schrijvers D; van den Eertwegh AJ; Li W; Molina A; Griffin TW; Kheoh T; Ricci DS; Zelinsky K; Rathkopf DE; Scher HI; Ryan CJ
    Clin Cancer Res; 2015 Apr; 21(7):1621-7. PubMed ID: 25593303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study.
    Detassis S; Precazzini F; Grasso M; Del Vescovo V; Maines F; Caffo O; Campomenosi P; Denti MA
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO].
    Rexer H; Hammerer P; Schostak M; König F
    Urologe A; 2017 Dec; 56(12):1615-1617. PubMed ID: 29071394
    [No Abstract]   [Full Text] [Related]  

  • 34. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer.
    Thortzen A; Thim S; Røder MA; Brasso K
    Urol Oncol; 2016 Jul; 34(7):291.e1-7. PubMed ID: 26971191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
    Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
    BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer.
    Suzuki K; Sakamoto M; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Anticancer Res; 2018 Oct; 38(10):5929-5935. PubMed ID: 30275221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
    Stover JT; Moore RA; Davis K; Harrison MR; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):161-6. PubMed ID: 25777155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
    Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
    Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.